Abstract
Today sintering of inflow cannulae in left ventricular assist devices (LVAD) is accepted as standard to ensure good myocardial ingrowth, preventing thrombus formation at the apical penetration site. Various studies like the ADVANCE trial compared the formerly polished pump of the HeartWare HVAD and the sintered version commercialized since 2012, investigating the incidence of pump thrombosis and thromboembolic complications. Though this is of essential clinical importance, it is only a surrogate for inflow cannula thrombus development.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
